Hal Landy serves as Chief Medical Officer of Phoenix Tissue Repair and is a board-certified pediatric endocrinologist with over 30 years of clinical research experience in academics and industry, primarily in rare diseases. Dr. Landy has served as a medical consultant to biotech and venture capital companies in diverse indications including vaccines and anti-infective antibodies, lysosomal and glycogen storage disorders, life-threatening genetic skin disorders, central nervous system disorders, hereditary anemia and neuromuscular disease. He has represented companies before numerous regulatory authorities including the FDA, EMA, MHRA and Health Canada, and before patient advocacy groups and boards of directors. Previously, Dr. Landy was involved in PTR-01’s early development at Lotus Tissue Repair, which was acquired by Shire prior to Phoenix Tissue Repair securing rights to the PTR-01 program. He was also Chief Medical Officer at Enobia Pharma, where he led its clinical program in hypophosphatasia, a rare and devastating disorder of skeletal mineralization, until its acquisition by Alexion in 2012. He also worked at Genzyme, where he was VP, Clinical Research and assisted in the registration of Aldurazyme for MPS-1 and Myozyme for Pompe Disease. Educated at Harvard College (A.B. ’72) and Columbia University (M.D. ’81), he trained at Massachusetts General Hospital and at Children’s Hospital, Boston and was on staff at Children’s Hospital and Harvard Medical School until 1996. He has authored or co-authored over 20 peer-reviewed articles and chapters.